Evidence map›Paper›PMID 37582699›Full record

ArticleBMC nephrology2023

Design and methodology of the SARCopenia trajectories and associations with adverse clinical outcomes in patients on HemoDialysis: the SARC-HD study.

Marvery P Duarte, Marina S Pereira, Victor M Baião, Fábio A Vieira, Maryanne Zilli Canedo Silva, Rodrigo R Krug, Antônio J Inda-Filho, Aparecido P Ferreira, Ricardo M Lima, Carla Maria Avesani and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Osteosarcopenia in Chronic Kidney Disease: An Overlooked Syndrome?Journal of cachexia, sarcopenia and muscle · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marvery P DuarteFaculty of Health Sciences, University of Brasilia, Brasília, Brazil.
Marina S PereiraPulmonary and Critical Care Division, University Hospital of Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
Victor M BaiãoFaculty of Health Sciences, University of Brasilia, Brasília, Brazil.
Fábio A VieiraIdealCor Physiotherapy, Brasília, Brazil.
Maryanne Zilli Canedo SilvaInternal Medicine Department, Botucatu Medical School, São Paulo State University, UNESP, Botucatu, Brazil.
Rodrigo R KrugUniversity of Cruz Alta, Cruz Alta, Brazil.
Antônio J Inda-FilhoInterdisciplinary Research Department, University Center ICESP, Brasilia, Brazil.
Aparecido P FerreiraInterdisciplinary Research Department, University Center ICESP, Brasilia, Brazil.
Ricardo M LimaFaculty of Physical Education, University of Brasilia, Brasília, Brazil.
Carla Maria AvesaniDepartment of Clinical Science, Technology and Intervention, Division of Renal Medicine and Baxter Novum, Karolinska Institute, Stockholm, Sweden.
Otávio T NóbregaFaculty of Health Sciences, University of Brasilia, Brasília, Brazil.
Maycon M Reboredo *Pulmonary and Critical Care Division, University Hospital of Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil.
Heitor S Ribeiro *Faculty of Health Sciences, University of Brasilia, Brasília, Brazil. heitor.ribeiro@icesp.edu.br.
SARC-HD Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcopenia has been associated with adverse outcomes in patients with chronic kidney disease (CKD), particularly in those undergoing hemodialysis (HD). However, the trajectories across sarcopenia stages, their determinants, and associations with adverse clinical outcomes have yet to be comprehensively examined.

methodsThe SARC-HD is a multicenter, observational prospective cohort study designed to comprehensively investigate sarcopenia in patients on HD. Eligibility criteria include adult patients undergoing HD for ≥ 3 months. The primary objective is to investigate the trajectories of sarcopenia stages and their potential determinants. Secondary objectives include evaluating the association between sarcopenia and adverse clinical outcomes (i.e., falls, hospitalization, and mortality). Sarcopenia risk will be assessed by the SARC-F and SARC-CalF questionnaire. Sarcopenia traits (i.e., low muscle strength, low muscle mass, and low physical performance) will be defined according to the revised European Working Group on Sarcopenia in Older People and will be assessed at baseline and after 12 follow-up months. Patients will be followed-up at 3 monthly intervals for adverse clinical outcomes during 24 months. DISCUSSION: Collectively, we expect to provide relevant clinical findings for healthcare professionals from nephrology on the association between sarcopenia screening tools (i.e., SARC-F and SARC-CalF) with objective sarcopenia measurements, as well as to investigate predictors of trajectories across sarcopenia stages, and the impact of sarcopenia on adverse clinical outcomes. Hence, our ambition is that the data acquired from SARC-HD study will provide novel and valuable evidence to support an adequate screening and management of sarcopenia in patients on HD.

Indexed as

SarcopeniaAgedGeriatric AssessmentHumansLegMass ScreeningMuscle StrengthPatientsProspective StudiesSurveys and QuestionnairesChronic kidney diseaseDialysisPhysical functionSARC-FSarcopenia

Identifiers

PMID37582699
PMCPMC10428584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.